Dyne Therapeutics (Nasdaq:DYN) - Hisse Senedi Fiyatı, Haberler ve Analizler

DYN Stoklara Genel Bakış

DYN temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Analistler hisse senedi fiyatının 74.5% oranında artacağı konusunda hemfikir

Risk Analizi

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Geliri 1 milyon ABD dolarından az ( $0 )

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Son 3 ayda dalgalı hisse senedi fiyatı

Dyne Therapeutics, Inc. Rakipler

Veracyte

NasdaqGM:VCYT

US$3.1b

Xenon Pharmaceuticals

NasdaqGM:XENE

US$3.1b

Merus

NasdaqGM:MRUS

US$3.1b

Vera Therapeutics

NasdaqGM:VERA

US$3.1b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Dyne Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$29.45
52 Haftanın En Yüksek Seviyesi	US$47.45
52 Haftanın En Düşük Seviyesi	US$10.12
Beta	1.1
11 Aylık Değişim	-4.17%
3 Aylık Değişim	-33.11%
1 Yıllık Değişim	176.27%
33 Yıllık Değişim	105.51%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	23.22%

Son Haberler & Güncellemeler

Recent updates

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Nov 12

Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases

Nov 11

Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street

Sep 04

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Aug 14

Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials

May 21

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

May 04

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Mar 05

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dec 05

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

Aug 09

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Mar 26

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dec 10

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Aug 26

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Jul 12

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Jul 05

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 05

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Jan 12

We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth

Sep 29

Dyne Therapeutics' chief scientific officer Romesh Subramanian steps down

Jun 02

Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 12

Dyne Therapeutics EPS beats by $0.10

May 06

Hissedar Getirileri

	DYN	US Biotechs	US Pazar
7D	0.4%	4.0%	2.2%
1Y	176.3%	18.3%	32.6%

Getiri vs. Endüstri: DYN geçen yıl % 18.3 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: DYN geçen yıl % 32.6 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is DYN's price volatile compared to industry and market?
DYN volatility
DYN Average Weekly Movement	12.0%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: DYN hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: DYN 'nin haftalık oynaklığı ( 12% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2017	173	John Cox	www.dyne-tx.com

Klinik aşamada bir kas hastalığı şirketi olan Dyne Therapeutics, Inc., Amerika Birleşik Devletleri'nde genetik olarak yönlendirilen kas hastalıkları için terapötikler geliştirmeye odaklanan bir biyoteknoloji şirketi olarak faaliyet göstermektedir. Hastalık modifiye edici terapötikler sunan FORCE platformunu kullanarak miyotonik distrofi tip 1; duchenne musküler distrofi; ve fasiyoskapulohumeral distrofi programlarının yanı sıra nadir iskelet kası, kardiyak ve metabolik kas hastalıkları da dahil olmak üzere bir kas hastalığı terapötikleri portföyü geliştirmektedir. Dyne Therapeutics, Inc. 2017 yılında kurulmuştur ve merkezi Waltham, Massachusetts'tedir.

Dyne Therapeutics, Inc. Temel Bilgiler Özeti

Dyne Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
DYN temel i̇stati̇sti̇kler
Piyasa değeri	US$3.02b
Kazançlar(TTM)	-US$294.51m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-10.2x

F/K Oranı

DYN aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
DYN gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$294.51m
Kazançlar	-US$294.51m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-2.89
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

DYN uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

DYN Stoklara Genel Bakış

Ödüller

Risk Analizi

Dyne Therapeutics, Inc. Rakipler

NasdaqGM:VCYT

US$3.1b

NasdaqGM:XENE

US$3.1b

NasdaqGM:MRUS

US$3.1b

NasdaqGM:VERA

US$3.1b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases

CEO, President & Director recently bought US$1.1m worth of stock

Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street

Dyne Therapeutics, Inc Announces Management Changes

Recent updates

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases

CEO, President & Director recently bought US$1.1m worth of stock

Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street

Dyne Therapeutics, Inc Announces Management Changes

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Price target increased by 8.9% to US$50.00

Chief Operating Officer notifies of intention to sell stock

Dyne Therapeutics, Inc. Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

Chief Operating Officer notifies of intention to sell stock

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $325.5 million.

New major risk - Shareholder dilution

Chief Scientific Officer notifies of intention to sell stock

Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dyne Therapeutics, Inc., Annual General Meeting, May 22, 2024

Dyne Therapeutics, Inc. Announces Chief Executive Officer Changes

CEO, President & Director recently sold US$223k worth of stock

Chief Operating Officer recently sold US$725k worth of stock

Price target increased by 8.3% to US$37.56

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

CEO, President & Director notifies of intention to sell stock

Chief Business Officer exercised options and sold US$476k worth of stock

New major risk - Shareholder dilution

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.125 million.

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.125 million.

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $175 million.

Chief Business Officer notifies of intention to sell stock

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Chief Operating Officer notifies of intention to sell stock

New major risk - Financial position

CEO, President & Director notifies of intention to sell stock

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

New major risk - Financial position

Insufficient new directors

CEO, President & Director recently sold US$618k worth of stock

CEO, President & Director notifies of intention to sell stock

Dyne Therapeutics, Inc. Announces Resignation of Dr. Lawrence Klein as Board Member

Insufficient new directors

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Price target increased by 9.6% to US$28.50

Insider exercised options and sold US$133k worth of stock

Insider notifies of intention to sell stock

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dyne Therapeutics, Inc. Receives Fda Fast Track Designation for Dyne-251 for the Treatment of Duchenne Muscular Dystrophy

CEO, President & Director exercised options and sold US$2.4m worth of stock

Dyne Therapeutics, Inc. Presents Preclinical Data from Its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 At World Muscle Society 2022 Congress

Dyne Therapeutics, Inc. Prioritizes its Focus and Resources on its Clinical Programs, DYNE-101 in DM1 and DYNE-251 in DMD

Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne Therapeutics, Inc. Appoints Francesco Bibbiani as Senior Vice President, Head of Development

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Dyne Therapeutics, Inc. Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research

High number of new directors

Price target decreased to US$24.67

Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate